Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lumateperone versus placebo in bipolar depression
2017-002317-58Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Lumateperone with Placebo (2 arms). Primary endpoint: Change from baseline to Day 43 in MADRS total score. Started Nov 2017; status: completed.
02
Drugs
lumateperone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2017-002317-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002317-58.